These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 11205218

  • 1. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
    Tsavaris N, Kosmas C, Mylonakis N, Bacoyiannis C, Kalergis G, Vadiaka M, Boulamatsis D, Iakovidis V, Kosmidis P.
    Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
    Tsavaris N, Kosmas CH, Vadiaka M, Kontos A, Katsorida M, Dimitrakopoulos A, Zerai A, Koufos CH.
    J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
    [Abstract] [Full Text] [Related]

  • 3. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [Abstract] [Full Text] [Related]

  • 4. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT, Raisch DW, Frost J.
    Cancer; 2006 Feb 15; 106(4):931-40. PubMed ID: 16404740
    [Abstract] [Full Text] [Related]

  • 5. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P, Manusirivithaya S, Tangjitgamol S, Thavaramara T, Sukwattana P.
    J Med Assoc Thai; 2006 Oct 15; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [Abstract] [Full Text] [Related]

  • 6. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A, Ratanatharathorn V, Sinlarat P, Chindavijak K, Lousoontornsiri W, Chakrapee-Sirisuk S, Srimuninimit V.
    J Med Assoc Thai; 1994 Apr 15; 77(4):201-6. PubMed ID: 7844494
    [Abstract] [Full Text] [Related]

  • 7. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.
    Cancer; 2002 Jun 01; 94(11):3032-41. PubMed ID: 12115394
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 Dec 01; 88(12):1790-6. PubMed ID: 16518975
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.
    O'Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F.
    CMAJ; 1993 Aug 01; 149(3):296-302. PubMed ID: 8339175
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.
    Cancer; 2003 May 01; 97(9):2290-300. PubMed ID: 12712486
    [Abstract] [Full Text] [Related]

  • 18. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
    Sarcev T, Secen N, Povazan Dj, Sabo A, Popovic J, Bursac D, Kakas M, Zaric B, Milovancev A.
    J BUON; 2007 May 01; 12(2):245-52. PubMed ID: 17600880
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
    Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR.
    Cancer; 2003 Jun 01; 97(11):2880-6. PubMed ID: 12767103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.